Avanos Medical, Inc. (AVNS) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Hold
Based on 8 analysts7.8% Above Target
AVNS trades 7.8% above Wall Street's consensus target of $23.00.
Current Price$24.94
Average Target$23.00
Target
Current
Low$20.00
Median$23.00
High$26.00
Analyst Target Range
Forward P/E24.9x
(Fair)
PEG Ratio—
Implied Growth+166.9%
(High Growth)
Analyst Spread26.1%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes AVNS achieves its forward estimates and maintains a stable P/E multiple of 24.9x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
AVNS Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Avanos Medical, Inc. (AVNS) has a Wall Street consensus price target of $23.00, based on estimates from 8 covering analysts. With the stock currently trading at $24.94, this represents a potential downside of -7.8%. The company has a market capitalization of $1.17B.
Analyst price targets range from a low of $20.00 to a high of $26.00, representing a 26% spread in expectations. The median target of $23.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 1 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 1 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, AVNS trades at a trailing P/E of -17.1x and forward P/E of 24.9x. Analysts expect EPS to grow +166.9% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+42.3%
Industry Consensus
Avg Forward P/E
121.9x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MMSIMerit Medical Systems, Inc. | $4.0B | $67.22 | $94.20 | +40.1% | Buy | 16.5x | 14 |
 NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
 ITGRInteger Holdings Corporation | $3.1B | $90.96 | $108.00 | +18.7% | Buy | 15.0x | 15 |
 ATRCAtriCure, Inc. | $1.5B | $28.80 | $51.33 | +78.2% | Buy | 768.0x | 19 |
 NTRANatera, Inc. | $33.1B | $231.41 | $259.88 | +12.3% | Buy | — | 27 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 ICUIICU Medical, Inc. | $3.5B | $140.37 | $165.50 | +17.9% | Buy | 17.2x | 11 |
 ANGOAngioDynamics, Inc. | $505M | $12.15 | $16.50 | +35.8% | Hold | — | 11 |
 INVAInnoviva, Inc. | $1.7B | $22.49 | $37.00 | +64.5% | Buy | 6.3x | 10 |
 MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
AVNS — Frequently Asked Questions
Quick answers to the most common questions about buying AVNS stock.
What is the AVNS stock price target for 2026?
Wall Street's consensus price target for AVNS is $23, -7.8% from its current price of $24.94. The below-market target from 8 analysts suggests limited near-term appreciation.
Is AVNS a buy, sell, or hold?
AVNS has a consensus rating of "Hold" based on 8 Wall Street analysts. The rating breakdown is mixed, with 6 Hold ratings making up the largest segment. The consensus 12-month price target of $23 implies -7.8% downside from current levels.
Is AVNS stock overvalued or undervalued?
AVNS trades at a forward P/E of 24.94x, representing a moderate valuation. With analysts targeting $23 (-7.8% implied move), the stock appears close to fair value.
How high can AVNS stock go?
The most bullish Wall Street analyst has a price target of $26 for AVNS, while the most conservative target is $20. The consensus of $23 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover AVNS stock?
AVNS is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 6 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the AVNS stock forecast?
The 12-month AVNS stock forecast based on 8 Wall Street analysts shows a consensus price target of $23, with estimates ranging from $20 (bear case) to $26 (bull case). The median consensus rating is "Hold".
What is AVNS's forward P/E ratio?
AVNS trades at a forward P/E ratio of 24.9x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy AVNS stock?
Analysts are cautious on AVNS, with 1 Sell ratings and a price target of $23 (-7.8% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do AVNS price targets vary so much?
AVNS analyst price targets range from $20 to $26, a 26% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $23 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare